The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy
Abstract
Blockade of the protein–protein interaction between the transmembrane protein programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 has emerged as a promising immunotherapy for treating cancers. Using the technology of mirror‐image phage display, we developed the first hydrolysis‐resistant D‐peptide antagonists to target the PD‐1/PD‐L1 pathway. The optimized compound D PPA‐1 could bind PD‐L1 at an affinity of 0.51 μ M in vitro. A blockade assay at the cellular level and tumor‐bearing mice experiments indicated that D PPA‐1 could also effectively disrupt the PD‐1/PD‐L1 interaction in vivo. Thus D‐peptide antagonists may provide novel low‐molecular‐weight drug candidates for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Synthesis of Proteins by Native Chemical Ligation
Dawson, P. E., Muir, T. W., Clark-Lewis, I., & Kent, S. B. H. (1994) · Science · doi:10.1126/science.7973629 · Cited by 4,131
Using circular dichroism spectra to estimate protein secondary structure
Greenfield, N. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.202 · Cited by 4,014
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Rethinking amide bond synthesis
Pattabiraman, V. R., & Bode, J. W. (2011) · Nature · doi:10.1038/nature10702 · Cited by 2,164
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Protein-binding assays in biological liquids using microscale thermophoresis
Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D., & Duhr, S. (2010) · Nature Communications · doi:10.1038/ncomms1093 · Cited by 1,138
Wan, Q., & Danishefsky, S. J. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200704195 · Cited by 878
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
The role of junctional adhesion molecules in vascular inflammation
Weber, C., Fraemohs, L., & Dejana, E. (2007) · Nature Reviews Immunology · doi:10.1038/nri2096 · Cited by 503
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
Lin, D. Y.-W., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H.-P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., & Garboczi, D. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712278105 · Cited by 457
Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., & Kim, P. S. (1999) · Cell · doi:10.1016/s0092-8674(00)80066-5 · Cited by 442
Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci
Veiseh, M., Gabikian, P., Bahrami, S.-B., Veiseh, O., Zhang, M., Hackman, R. C., Ravanpay, A. C., Stroud, M. R., Kusuma, Y., Hansen, S. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3948 · Cited by 422
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Convergent Chemical Synthesis of Proteins by Ligation of Peptide Hydrazides
Fang, G., Wang, J., & Liu, L. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203843 · Cited by 380
Self-citationIdentification of d -Peptide Ligands Through Mirror-Image Phage Display
Schumacher, T. N. M., Mayr, L. M., Minor, D. L., Milhollen, M. A., Burgess, M. W., & Kim, P. S. (1996) · Science · doi:10.1126/science.271.5257.1854 · Cited by 376
Ntziachristos, V., Schellenberger, E. A., Ripoll, J., Yessayan, D., Graves, E., Bogdanov, A., Josephson, L., & Weissleder, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401137101 · Cited by 348
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335
Potent D-peptide inhibitors of HIV-1 entry
Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., & Kay, M. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708109104 · Cited by 250
Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 228
Differential binding properties of B7-H1 and B7-DC to programmed death-1
Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H., Omura, K., Yagita, H., Pardoll, D. M., Chen, L., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01257-9 · Cited by 209
Pentelute, B. L., & Kent, S. B. H. (2007) · Organic Letters · doi:10.1021/ol0630144 · Cited by 199
Peptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors
Molek, P., Strukelj, B., & Bratkovic, T. (2011) · Molecules · doi:10.3390/molecules16010857 · Cited by 187
Wiesehan, K., Buder, K., Linke, R. P., Patt, S., Stoldt, M., Unger, E., Schmitt, B., Bucci, E., & Willbold, D. (2003) · ChemBioChem · doi:10.1002/cbic.200300631 · Cited by 171
Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer
Brahmer, J. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8703 · Cited by 162
Mandal, K., Uppalapati, M., Ault-Riché, D., Kenney, J. S., Lowitz, J., Sidhu, S. S., & Kent, S. B. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210483109 · Cited by 151
Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity
Weinstock, M. T., Jacobsen, M. T., & Kay, M. S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410900111 · Cited by 148
van Groen, T., Wiesehan, K., Funke, S. A., Kadish, I., Nagel‐Steger, L., & Willbold, D. (2008) · ChemMedChem · doi:10.1002/cmdc.200800273 · Cited by 140
A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201000329 · Cited by 115
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307906 · Cited by 72
Convergent Chemical Synthesis of Proteins by Ligation of Peptide Hydrazides
Fang, G., Wang, J., & Liu, L. (2012) · Angewandte Chemie · doi:10.1002/ange.201203843 · Cited by 62
Self-citationA Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
Liu, M., Pazgier, M., Li, C., Yuan, W., Li, C., & Lu, W. (2010) · Angewandte Chemie · doi:10.1002/ange.201000329 · Cited by 10
Programmed Death‐1: therapeutischer Erfolg nach über 100 Jahren Krebsimmuntherapie
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie · doi:10.1002/ange.201307906 · Cited by 9
Research works printed but not linked: 3
- 10.1023/A:1016440707092 · doi:10.1023/a:1016440707092
- 10.1039/C4CC00779D · doi:10.1039/c4cc00779d
- 10.1002/ange.200704195 · doi:10.1002/ange.200704195
Cited by
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 414
Wang, D., Wang, T., Liu, J., Yu, H., Jiao, S., Feng, B., Zhou, F., Fu, Y., Yin, Q., Zhang, P., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b01994 · Cited by 405
Metadata
- Authors
- Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., Qi, Y., Liu, L., & Gao, Y.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2015-08-10
- Volume
- 54
- Issue
- 40
- Pages
- 11760-11764
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2165838507
- Cited by
- 397
- References
- 47
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- NSFC (81172893, 91442121, 91313301, 21225207)
- “863” Program of the Ministry of Science and Technology (2012AA02A700)
- National Basic Research Program of China (2013CB932800)
- Outstanding Talent Project of Henan Province (134100510015)
- Zhengzhou University (1421311081)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.